Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Relatlimab in combination with nivolumab for advanced melanoma – second line	Nivolumab (Opdivo; BMS-936558; ONO-4538) , Relatlimab (BMS-986016; Anti-LAG-3)	Melanoma	Skin Cancer	2019	View \| Download
Risdiplam for paediatric and adult patients with spinal muscular atrophy (SMA)	Risdiplam (RG-7916; RO-7034067; Evrysdi)	Spinal muscular atrophy (SMA)	Genetic Disorders , Musculoskeletal System	2019	View \| Download
Rivaroxaban for reducing the risk of major thrombotic vascular events in symptomatic peripheral arterial disease patients with a recent lower extremity revascularisation procedure	Rivaroxaban (Xarelto; BAY 59-7939)	Peripheral arterial disease (PAD)	Cardiovascular System	2019	View \| Download
Romiplostim for idiopathic thrombocytopenic purpura in adult patients who are refractory to other treatments	Romiplostim (Nplate; AMG-531)	Idiopathic thrombocytopenic purpura	Haematology	2019	View \| Download
Ropeginterferon alfa-2b for polycythaemia vera without symptomatic splenomegaly	Ropeginterferon alfa 2-b (P-1101; AOP2014; Pegylated-Proline-interferon alpha-2b)	Polycythaemia vera	Haematological Cancer and Lymphomas	2019	View \| Download
Ruxolitinib for acute graft versus host disease (aGvHD)	Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate)	Graft versus host disease (GvHD)	Immunology	2019	View \| Download
Ruxolitinib for chronic graft versus host disease (cGvHD)	Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate)	Graft versus host disease (GvHD)	Immunology	2019	View \| Download
Savolitinib for MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma	Savolitinib (AZD6094)	Renal cell carcinoma (RCC)	Renal Cancer	2019	View \| Download
Secukinumab for enthesitis-related arthritis and juvenile psoriatic arthritis in children and adolescents from the age of 2 years	Secukinumab (Cosentyx; AIN457)	Enthesitis-related arthritis , Juvenile psoriatic arthritis	Rheumatology	2019	View \| Download
Secukinumab for moderate to severe plaque psoriasis in children aged 6 to less than 18 years old	Secukinumab (Cosentyx; AIN457)	Plaque psoriasis	Dermatology	2019	View \| Download